Fezagepras NEW

Price	$35	$81	$123
Package	1mg	5mg	10mg

Supply Ability:	10g
Update Time:	2026-06-09

Product Details

Product Name: Fezagepras	CAS No.: 1002101-19-0
Purity: 97.70%	Supply Ability: 10g
Release date: 2026/06/09

Product Introduction

Bioactivity

Name	Fezagepras
Description	Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions.
In vitro	TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation inhibited by Setogepram (PBI-4050; 500 μM; 24 hours). Setogepram (PBI-4050; 250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis [2].
In vivo	In type 2 diabetes eNOS-/-db/db mice, Setogepram (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improve glucose tolerance [1].
Storage	Pure form: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 60 mg/mL (290.87 mM), Sonication is recommended. 10% DMSO+90% Saline : 5 mg/mL (24.24 mM), Sonication is recommended.
Keywords	PBI4050 \| PBI 4050 \| Inhibitor \| inhibit \| GPR84 \| GPR40 \| G protein coupled receptor 84 \| Free Fatty Acid Receptor \| FFAR \| Fezagepras \| Diabetes,Kidney,Renal,Pancreatic,Liver,Fibrosis,Nephrology
Inhibitors Related	Monomethyl fumarate \| Kynurenic acid \| Pamoic acid disodium \| Azathioprine \| CRTh2 antagonist 2 \| Fezagepras sodium \| Benzyl nicotinate \| 1-methoxycyclopropanecarboxylic acid \| TUG-1375 \| CAY10595 \| TUG-424 \| Timapiprant
Related Compound Libraries	Failed Clinical Trials Compound Library \| Bioactive Compound Library \| Membrane Protein-targeted Compound Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| Inhibitor Library \| Anti-Aging Compound Library \| Immunology/Inflammation Compound Library \| Bioactive Compounds Library Max \| GPCR Compound Library \| Anti-Cancer Compound Library \| Anti-Cancer Drug Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.